Biochemical premotor biomarkers for Parkinson's disease

Movement Disorders

Volumn 27, Issue 5, 2012, Pages 644-650

  Mollenhauer, Brit ^a   Zhang, Jing ^b  

^a UNIVERSITY OF GÖTTINGEN   (Germany)

^b UNIVERSITY OF WASHINGTON   (United States)

Author keywords

Biomarkers; Genomics; Metabolomics; Parkinson's disease; Premotor; Proteomics

Indexed keywords

ALPHA SYNUCLEIN; ANTIOXIDANT; DJ 1 PROTEIN; LEUCINE RICH REPEAT KINASE 2; MESSENGER RNA; URATE;

ARTICLE; CEREBROSPINAL FLUID; CONSTIPATION; DEPRESSION; DIFFUSE LEWY BODY DISEASE; DISEASE MODEL; DISEASE SEVERITY; DISORDERS OF MITOCHONDRIAL FUNCTIONS; ENZYME LINKED IMMUNOSORBENT ASSAY; FAMILIAL DISEASE; GEL ELECTROPHORESIS; GENE MUTATION; GENETIC TRANSCRIPTION; METABOLOMICS; NONHUMAN; OLFACTORY NERVE DISEASE; OXIDATIVE STRESS; PARASOMNIA; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN FOLDING; REM SLEEP; RNA SPLICING; SHY DRAGER SYNDROME; STANDARDIZATION; TRANSCRIPTOMICS;

ALPHA-SYNUCLEIN; BIOLOGICAL MARKERS; EARLY DIAGNOSIS; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; ONCOGENE PROTEINS; PARKINSON DISEASE;

EID: 84859819081     PISSN: 08853185     EISSN: 15318257     Source Type: Journal    
DOI: 10.1002/mds.24956     Document Type: Article

References (61)

1. Hughes AJ, Daniel SE, Kilford L, Lees AJ. Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry. 1992; 55: 181-184.
2. Chaudhuri KR, Naidu Y. Early Parkinson's disease and non-motor issues. J Neurol. 2008; 255( Suppl 5): 33-38.
3. Del Tredici K, Hawkes CH, Ghebremedhin E, Braak H. Lewy pathology in the submandibular gland of individuals with incidental Lewy body disease and sporadic Parkinson's disease. Acta Neuropathol. 2010; 119: 703-713.
4. Valappil RA, Black JE, Broderick MJ, et al. Exploring the electrocardiogram as a potential tool to screen for premotor Parkinson's disease. Mov Disord. 2010; 25: 2296-2303.
5. Masilamoni GJ, Bogenpohl JW, Alagille D, et al. Metabotropic glutamate receptor 5 antagonist protects dopaminergic and noradrenergic neurons from degeneration in MPTP-treated monkeys. Brain. 2011; 134: 2057-2073.
6. Dehay B, Bezard E. New animal models of Parkinson's disease. Mov Disord. 2011; 26: 1198-1205.
7. Andreasen N, Minthon L, Davidsson P, et al. Evaluation of CSF-tau and CSF-Abeta42 as diagnostic markers for Alzheimer disease in clinical practice. Arch Neurol. 2001; 58: 373-379.
8. Peskind ER, Riekse R, Quinn JF, et al. Safety and acceptability of the research lumbar puncture. Alzheimer Dis Assoc Disord. 2005; 19: 220-225.
9. Reiber H. Dynamics of brain-derived proteins in cerebrospinal fluid. Clin Chim Acta. 2001; 310: 173-186.
10. Reiber H. Flow rate of cerebrospinal fluid (CSF)--a concept common to normal blood-CSF barrier function and to dysfunction in neurological diseases. J Neurol Sci. 1994; 122: 189-203.
11. Le WD, Rowe DB, Jankovic J, Xie W, Appel SH. Effects of cerebrospinal fluid from patients with Parkinson disease on dopaminergic cells. Arch Neurol. 1999; 56: 194-200.
12. Yu SJ, Lo ES, Cochran EJ, et al. Cerebrospinal fluid from patients with Parkinson's disease alters the survival of dopamine neurons in mesencephalic culture. Exp Neurol. 1994; 126: 15-24.
13. Harrington MG, Merril CR. Cerebrospinal fluid protein analysis in diseases of the nervous system. J Chromatogr. 1988; 429: 345-358.
14. Spillantini MG, Schmidt ML, Lee VM, Trojanowski JQ, Jakes R, Goedert M. Alpha-synuclein in Lewy bodies. Nature. 1997; 388: 839-840.
15. Gai WP, Power JH, Blumbergs PC, Blessing WW. Multiple-system atrophy: a new alpha-synuclein disease? Lancet. 1998; 352: 547-548.
16. El-Agnaf OM, Salem SA, Paleologou KE, et al. Alpha-synuclein implicated in Parkinson's disease is present in extracellular biological fluids, including human plasma. FASEB J. 2003; 17: 1945-1947.
17. Desplats P, Lee HJ, Bae EJ, et al. Inclusion formation and neuronal cell death through neuron-to-neuron transmission of alpha-synuclein. Proc Natl Acad Sci U S A. 2009; 106: 13010-13015.
18. Devic I, Hwang H, Edgar JS, et al. Salivary alpha-synuclein and DJ-1: potential biomarkers for Parkinson's disease. Brain. 2011; 134: e178.
19. Mollenhauer B, El-Agnaf OM, Marcus K, Trenkwalder C, Schlossmacher MG. Quantification of alpha-synuclein in cerebrospinal fluid as a biomarker candidate: review of the literature and considerations for future studies. Biomark Med. 2010; 4: 683-699.
20. Shi M, Bradner J, Hancock AM, et al. Cerebrospinal fluid biomarkers for Parkinson disease diagnosis and progression. Ann Neurol. 2011; 69: 570-580.
21. Aerts MB, Esselink RA, Abdo WF, Bloem BR, Verbeek MM. CSF alpha-synuclein does not differentiate between parkinsonian disorders. Neurobiol Aging. 2011; 33: 430.e1-430.e3.
22. Cantuti-Castelvetri I, Klucken J, Ingelsson M, et al. Alpha-synuclein and chaperones in dementia with Lewy bodies. J Neuropathol Exp Neurol. 2005; 64: 1058-1066.
23. Beyer K, Humbert J, Ferrer A, et al. Low alpha-synuclein 126 mRNA levels in dementia with Lewy bodies and Alzheimer disease. Neuroreport. 2006; 17: 1327-1330.
24. Anderson JP, Walker DE, Goldstein JM, et al. Phosphorylation of Ser 129 is the dominant pathological modification of alpha -synuclein in familial and sporadic Lewy body disease. J Biol Chem. 2006; 281: 29739-29752.
25. Chodobski A, Szmydynger-Chodobska J. Choroid plexus: target for polypeptides and site of their synthesis. Microsc Res Tech. 2001; 52: 65-82.
26. Tokuda T, Salem SA, Allsop D, et al. Decreased alpha-synuclein in cerebrospinal fluid of aged individuals and subjects with Parkinson's disease. Biochem Biophys Res Commun. 2006; 349: 162-166.
27. El-Agnaf OM, Salem SA, Paleologou KE, et al. Detection of oligomeric forms of alpha-synuclein protein in human plasma as a potential biomarker for Parkinson's disease. FASEB J. 2006; 20: 419-425.
28. Tokuda T, Qureshi MM, Ardah MT, et al. Detection of elevated levels of {alpha}-synuclein oligomers in CSF from patients with Parkinson disease. Neurology. 2010; 75: 1766-1772.
29. Bonifati V, Oostra BA, Heutink P. Linking DJ-1 to neurodegeneration offers novel insights for understanding the pathogenesis of Parkinson's disease. J Mol Med. 2004; 82: 163-174.
30. Choi J, Sullards MC, Olzmann JA, et al. Oxidative damage of DJ-1 is linked to sporadic Parkinson and Alzheimer diseases. J Biol Chem. 2006; 281: 10816-10824.
31. Waragai M, Wei J, Fujita M, et al. Increased level of DJ-1 in the cerebrospinal fluids of sporadic Parkinson's disease. Biochem Biophys Res Commun. 2006; 345: 967-972.
32. Hong Z, Shi M, Chung KA, et al. DJ-1 and alpha-synuclein in human cerebrospinal fluid as biomarkers of Parkinson's disease. Brain. 2010; 133: 713-726.
33. Lowe JS, Leigh N. Disorders of movement and system degenerations. In: Graham DI, Lantos PL, eds. Greenfield's Neuropathology. Vol. II. London: Arnold; 2002: 325-430.
34. Cipriani S, Chen X, Schwarzschild MA. Urate: a novel biomarker of Parkinson's disease risk, diagnosis and prognosis. Biomark Med. 2010; 4: 701-712.
35. Lu L, Neff F, Dun Z, et al. Gene expression profiles derived from single cells in human postmortem brain. Brain Res Brain Res Protoc. 2004; 13: 18-25.
36. Grimm J, Mueller A, Hefti F, Rosenthal A. Molecular basis for catecholaminergic neuron diversity. Proc Natl Acad Sci U S A. 2004; 101: 13891-13896.
37. Caudle WM, Bammler TK, Lin Y, Pan S, Zhang J. Using 'omics' to define pathogenesis and biomarkers of Parkinson's disease. Expert Rev Neurother. 2010; 10: 925-942.
38. Scherzer CR, Eklund AC, Morse LJ, et al. Molecular markers of early Parkinson's disease based on gene expression in blood. Proc Natl Acad Sci U S A. 2007; 104: 955-960.
39. Scherzer CR, Grass JA, Liao Z, et al. GATA transcription factors directly regulate the Parkinson's disease-linked gene alpha-synuclein. Proc Natl Acad Sci U S A. 2008; 105: 10907-10912.
40. Klucken J, Shin Y, Masliah E, Hyman BT, McLean PJ. Hsp70 reduces alpha-aynuclein aggregation and roxicity. J Biol Chem. 2004; 279: 25497-25502.
41. Shadrina MI, Filatova EV, Karabanov AV, et al. Expression analysis of suppression of tumorigenicity 13 gene in patients with Parkinson's disease. Neurosci Lett. 2010; 473: 257-259.
42. Zhang J. Proteomics of human cerebrospinal fluid-the good, the bad, and the ugly. Proteomics Clin Appl. 2007; 1: 805-819.
43. Davidsson P, Sjogren M. The use of proteomics in biomarker discovery in neurodegenerative diseases. Dis Markers. 2005; 21: 81-92.
44. Abdi F, Quinn JF, Jankovic J, et al. Detection of biomarkers with a multiplex quantitative proteomic platform in cerebrospinal fluid of patients with neurodegenerative disorders. J Alzheimers Dis. 2006; 9: 293-348.
45. Pan S, Rush J, Peskind ER, et al. Application of targeted quantitative proteomics analysis in human cerebrospinal fluid using a liquid chromatography matrix-assisted laser desorption/ionization time-of-flight tandem mass spectrometer (LC MALDI TOF/TOF) platform. J Proteome Res. 2008; 7: 720-730.
46. Pan S, Zhu D, Quinn JF, et al. A combined dataset of human cerebrospinal fluid proteins identified by multi-dimensional chromatography and tandem mass spectrometry. Proteomics. 2007; 7: 469-473.
47. Ames BN, Cathcart R, Schwiers E, Hochstein P. Uric acid provides an antioxidant defense in humans against oxidant- and radical-caused aging and cancer: a hypothesis. Proc Natl Acad Sci U S A. 1981; 78: 6858-6862.
48. Ascherio A, LeWitt PA, Xu K, et al. Urate as a predictor of the rate of clinical decline in Parkinson disease. Arch Neurol. 2009; 66: 1460-1468.
49. Schwarzschild MA, Schwid SR, Marek K, et al. Serum urate as a predictor of clinical and radiographic progression in Parkinson disease. Arch Neurol. 2008; 65: 716-723.
50. Schlesinger I, Schlesinger N. Uric acid in Parkinson's disease. Mov Disord. 2008; 23: 1653-1657.
51. Weisskopf MG, O'Reilly E, Chen H, Schwarzschild MA, Ascherio A. Plasma urate and risk of Parkinson's disease. Am J Epidemiol. 2007; 166: 561-567.
52. Bogdanov M, Matson WR, Wang L, et al. Metabolomic profiling to develop blood biomarkers for Parkinson's disease. Brain. 2008; 131: 389-396.
53. Johansen KK, Wang L, Aasly JO, et al. Metabolomic profiling in LRRK2-related Parkinson's disease. PloS One. 2009; 4: e7551.
54. Jin J, Hulette C, Wang Y, et al. Proteomic identification of a stress protein, mortalin/mthsp70/GRP75: relevance to Parkinson disease. Mol Cell Proteomics. 2006; 5: 1193-1204.
55. Shi M, Jin J, Wang Y, et al. Mortalin: a protein associated with progression of Parkinson disease? J Neuropathol Exp Neurol, 2008; 67: 117-124.
56. Mattsson N, Blennow K, Zetterberg H. Inter-laboratory variation in cerebrospinal fluid biomarkers for Alzheimer's disease: united we stand, divided we fall. Clin Chem Lab Med. 2010; 48: 603-607.
57. Bibl M, Esselmann H, Otto M, et al. Cerebrospinal fluid amyloid beta peptide patterns in Alzheimer's disease patients and nondemented controls depend on sample pretreatment: indication of carrier-mediated epitope masking of amyloid beta peptides. Electrophoresis. 2004; 25: 2912-2918.
58. Petricoin EF, Ardekani AM, Hitt BA, et al. Use of proteomic patterns in serum to identify ovarian cancer. Lancet. 2002; 359: 572-577.
59. Olsson A, Vanderstichele H, Andreasen N, et al. Simultaneous measurement of {beta}-amyloid(1-42), total tau, and phosphorylated tau (Thr181) in cerebrospinal fluid by the xMAP technology. Clin Chem. 2005; 51: 336-345.
60. Zhang J, Solkal I, Peksind ER, et al. CSF multianalyte profile distinguishes Alzheimer and Parkinson diseases. Am J Clin Pathol. 2008; 129: 526-529.
61. Anderson L, Hunter CL. Quantitative mass spectrometric multiple reaction monitoring assays for major plasma proteins. Mol Cell Proteomics. 2006; 5: 573-588.